Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.40 |
| ▸ | CSNK1D | P48730 | 2/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719200 | 0.92 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4723794 | 0.86 | MAPK14 (0.48) | BRD4MAPKAPK2MAPK14GAARAB9A | |
| SCHEMBL4760720 | 0.81 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6004043 | 0.80 | CSNK1E (0.50) | MAPK14CSNK1DCSNK1E | |
| SCHEMBL6004454 | 0.79 | CSNK1E (0.47) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4723030 | 0.78 | MAPK14 (0.53) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4719198 | 0.78 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6004538 | 0.77 | MAPK14 (0.52) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL4760240 | 0.76 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11CSNK1D | |
| SCHEMBL6004035 | 0.75 | MAPK14 (0.45) | MAPK14MAPK13MAPK12MAPK11CSNK1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871770-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | Kalypsys, Inc. (US) | 2008-01-02 | — | — | EP | disclosed |
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | KALYPSYS, INC. | 2006-11-09 | — | — | US | disclosed |
| WO-2006116355-A1 | ORTHO-TERPHENYL INHIBITORS OF P38 KINASE AND METHODS OF TREATING INFLAMMATORY DISORDERS | KALYPSYS, INC. (US) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252807-A1 | Novel ortho-terphenyl inhibitors of p38 kinase and methods of treating inflammatory disorders | MAPK1, MAP3K1, MAPK4 | BRD4 1490/4885MAPKAPK2 10/4885MAPK14 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.